Co-Authors
This is a "connection" page, showing publications co-authored by Barney Graham and John Mascola.
Connection Strength
3.299
-
Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity. 2021 08 10; 54(8):1636-1651.
Score: 0.240
-
SARS-CoV-2 Viral Variants-Tackling a Moving Target. JAMA. 2021 04 06; 325(13):1261-1262.
Score: 0.235
-
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020 10; 586(7830):567-571.
Score: 0.224
-
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020 10 15; 383(16):1544-1555.
Score: 0.224
-
Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat Immunol. 2019 Jun; 20(6):765.
Score: 0.206
-
Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine. J Infect Dis. 2019 04 08; 219(Suppl_1):S107-S109.
Score: 0.204
-
Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. J Virol. 2018 05 15; 92(10).
Score: 0.191
-
Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases. JAMA. 2018 Apr 10; 319(14):1431-1432.
Score: 0.191
-
Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015 Jul 28; 6:7712.
Score: 0.158
-
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021 09 17; 373(6561):1372-1377.
Score: 0.060
-
COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity. 2021 08 10; 54(8):1869-1882.e6.
Score: 0.060
-
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021 Aug 13; 373(6556).
Score: 0.060
-
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell. 2021 08 05; 184(16):4203-4219.e32.
Score: 0.059
-
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021 06 10; 384(23):2259-2261.
Score: 0.059
-
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021 05 12; 13(593).
Score: 0.059
-
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021 05; 593(7857):130-135.
Score: 0.058
-
Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. Sci Transl Med. 2021 03 03; 13(583).
Score: 0.058
-
Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. Vaccines (Basel). 2021 Jan 21; 9(2).
Score: 0.058
-
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med. 2021 01 07; 384(1):80-82.
Score: 0.057
-
A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. Sci Rep. 2020 10 23; 10(1):18149.
Score: 0.057
-
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Rep. 2020 10 27; 33(4):108322.
Score: 0.057
-
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020 11 12; 383(20):1920-1931.
Score: 0.056
-
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV. 2019 10; 6(10):e667-e679.
Score: 0.052
-
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV. 2019 05; 6(5):e297-e306.
Score: 0.051
-
Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem. Cold Spring Harb Perspect Biol. 2018 07 02; 10(7).
Score: 0.048
-
Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. ACS Infect Dis. 2018 05 11; 4(5):788-796.
Score: 0.047
-
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med. 2018 01; 15(1):e1002493.
Score: 0.047
-
Functional interrogation and mining of natively paired human VH:VL antibody repertoires. Nat Biotechnol. 2018 02; 36(2):152-155.
Score: 0.047
-
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet. 2018 02 10; 391(10120):552-562.
Score: 0.047
-
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. PLoS One. 2017; 12(11):e0185959.
Score: 0.046
-
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. PLoS Med. 2017 Nov; 14(11):e1002435.
Score: 0.046
-
HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. J Virol. 2017 11 01; 91(21).
Score: 0.046
-
Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans. Sci Immunol. 2017 Jul 14; 2(13).
Score: 0.045
-
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Stat Commun Infect Dis. 2017 Jan; 9(1).
Score: 0.045
-
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial. NPJ Vaccines. 2017; 2:15.
Score: 0.045
-
DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis. 2011 Dec; 11(12):916-24.
Score: 0.030
-
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008 Nov 25; 26(50):6338-43.
Score: 0.025